AI Engines For more Details: Perplexity Kagi Labs You
Wakefulness-Promoting Effects: Modafinil is known for its ability to enhance wakefulness and alertness, particularly in individuals with conditions characterized by excessive daytime sleepiness. It helps reduce the tendency to fall asleep during the day and improves cognitive function and productivity.
Treatment of Narcolepsy: Narcolepsy is a neurological disorder characterized by excessive daytime sleepiness, sudden episodes of sleep (narcoleptic attacks), cataplexy (sudden loss of muscle tone), and disrupted nighttime sleep. Modafinil is an effective treatment option for narcolepsy, helping individuals manage symptoms and improve daytime functioning.
Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS): Modafinil may be prescribed as an adjunctive treatment for obstructive sleep apnea/hypopnea syndrome (OSAHS), a condition characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, leading to fragmented sleep and daytime sleepiness. It can help alleviate excessive daytime sleepiness and improve quality of life in individuals with OSAHS.
Shift Work Sleep Disorder (SWSD): Shift work sleep disorder is a circadian rhythm sleep disorder characterized by insomnia, excessive sleepiness, and impaired alertness during work hours due to irregular or rotating work schedules. Modafinil may be prescribed to individuals with SWSD to improve wakefulness and performance during shift work hours.
Minimal Abuse Potential: Modafinil is considered to have a low potential for abuse and dependence compared to other stimulant medications. It does not produce the same euphoric effects or withdrawal symptoms commonly associated with traditional stimulants like amphetamines.
Improvement in Cognitive Function: Modafinil has been shown to improve cognitive function, including attention, memory, and executive functioning, in healthy individuals and those with conditions associated with cognitive impairment. It may enhance productivity and performance in tasks requiring sustained attention and mental alertness.
Side Effects: Common side effects of modafinil may include headache, nausea, nervousness, insomnia, dry mouth, and gastrointestinal upset. These side effects are usually mild and transient, but some individuals may experience more severe reactions or allergic responses requiring medical attention.
Cardiovascular Effects: Modafinil may have cardiovascular effects, including increases in heart rate and blood pressure. It should be used with caution in individuals with pre-existing cardiovascular conditions, and regular monitoring of cardiovascular parameters may be necessary during treatment.
Psychiatric Effects: Modafinil may rarely cause psychiatric side effects such as anxiety, agitation, irritability, and mood changes. Patients with a history of psychiatric disorders should be closely monitored for exacerbation of symptoms while taking modafinil.
Interactions: Modafinil may interact with other medications, including hormonal contraceptives, anticoagulants, and certain antiepileptic drugs, potentially affecting their efficacy or safety. Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Anaerobutyricum hallii | Reduces |
| species | Bifidobacterium longum | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Blautia | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Clostridioides | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Bifidobacterium | genus | Decreases |
| 0 | 1 | Collinsella | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Blautia obeum | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Clostridioides difficile | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Wansuia hejianensis | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
| 1 | 0 | Bifidobacterium longum | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Collinsella aerofaciens | species | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. infantis | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. longum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suillum | subspecies | Decreases |
| 0 | 1 | Bifidobacterium longum subsp. suis | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0 | 0 | |
| ADHD | 0.4 | 0.1 | 3 |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.1 | 2 |
| Allergies | 1.3 | 0.5 | 1.6 |
| Allergy to milk products | 0.2 | 0.2 | 0 |
| Alopecia (Hair Loss) | 0.2 | 0.2 | |
| Alzheimer's disease | 0.7 | 0.5 | 0.4 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0.1 | 0 |
| Ankylosing spondylitis | 0.4 | 0.2 | 1 |
| Anorexia Nervosa | 0.4 | 0.4 | 0 |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 0.5 | 0.1 | 4 |
| Atherosclerosis | 0.2 | 0 | 0 |
| Atrial fibrillation | 0.5 | 0.1 | 4 |
| Autism | 0.8 | 0.5 | 0.6 |
| Autoimmune Disease | 0.1 | 0 | 0 |
| Barrett esophagus cancer | 0.1 | 0 | 0 |
| benign prostatic hyperplasia | 0 | 0 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 0.2 | 0.2 | 0 |
| Brain Trauma | 0.1 | 0.2 | -1 |
| Cancer (General) | 0.1 | 0.1 | 0 |
| Carcinoma | 0.4 | 0.4 | 0 |
| Celiac Disease | 0.1 | 0.5 | -4 |
| Cerebral Palsy | 0.2 | 0.4 | -1 |
| Chronic Fatigue Syndrome | 0.9 | 1.2 | -0.33 |
| Chronic Kidney Disease | 0.4 | 0 | 0 |
| Chronic Lyme | 0.2 | 0 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.1 | 1 |
| Chronic Urticaria (Hives) | 0.1 | 0.1 | |
| Coagulation / Micro clot triggering bacteria | 0 | 0.4 | 0 |
| Cognitive Function | 0.2 | 0.1 | 1 |
| Colorectal Cancer | 0.5 | 0.1 | 4 |
| Constipation | 0.2 | 0.2 | 0 |
| Coronary artery disease | 0.3 | 0.4 | -0.33 |
| COVID-19 | 1.2 | 1.8 | -0.5 |
| Crohn's Disease | 0.5 | 0.5 | 0 |
| Cushing's Syndrome (hypercortisolism) | 0 | 0 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0 | 0.2 | 0 |
| Denture Wearers Oral Shifts | 0.2 | 0.2 | |
| Depression | 0.5 | 0.7 | -0.4 |
| Dermatomyositis | 0 | 0 | 0 |
| Eczema | 0.1 | 0.2 | -1 |
| Endometriosis | 0.3 | 0.2 | 0.5 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.1 | 0 | 0 |
| Fibromyalgia | 0.2 | 0.1 | 1 |
| Functional constipation / chronic idiopathic constipation | 0.4 | 0.4 | 0 |
| gallstone disease (gsd) | 0.4 | 0 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.6 | -5 |
| Generalized anxiety disorder | 0.3 | 0.2 | 0.5 |
| giant cell arteritis | 0 | 0 | |
| Glioblastoma | 0 | 0 | |
| Gout | 0.2 | 0 | 0 |
| Graves' disease | 0.2 | 0.5 | -1.5 |
| Gulf War Syndrome | 0.3 | 0 | 0 |
| Halitosis | 0.1 | 0 | 0 |
| Hashimoto's thyroiditis | 0.5 | 0.1 | 4 |
| Heart Failure | 0.5 | 0.5 | 0 |
| Hidradenitis Suppurativa | 0.1 | 0.1 | 0 |
| High Histamine/low DAO | 0 | 0.1 | 0 |
| hypercholesterolemia (High Cholesterol) | 0 | 0 | |
| hyperglycemia | 0.2 | 0.3 | -0.5 |
| Hyperlipidemia (High Blood Fats) | 0 | 0 | 0 |
| hypersomnia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.4 | 0.5 | -0.25 |
| Hypothyroidism | 0.2 | -0.2 | |
| Hypoxia | 0.1 | 0.1 | |
| IgA nephropathy (IgAN) | 0.2 | 0.3 | -0.5 |
| Inflammatory Bowel Disease | 0.6 | 1.3 | -1.17 |
| Insomnia | 0.6 | 0.5 | 0.2 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.4 | 0 | 0 |
| Irritable Bowel Syndrome | 0.6 | 0.5 | 0.2 |
| ischemic stroke | 0.5 | 0 | 0 |
| Liver Cirrhosis | 0.7 | 0.3 | 1.33 |
| Long COVID | 0.5 | 1.2 | -1.4 |
| Low bone mineral density | 0 | 0 | |
| Lung Cancer | 0.4 | -0.4 | |
| Mast Cell Issues / mastitis | 0 | 0.2 | 0 |
| ME/CFS with IBS | 0.1 | 1 | -9 |
| ME/CFS without IBS | 0.2 | 0.3 | -0.5 |
| membranous nephropathy | 0 | 0 | |
| Menopause | 0.2 | 0.2 | |
| Metabolic Syndrome | 0.5 | 0.7 | -0.4 |
| Mood Disorders | 0.8 | 0.6 | 0.33 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.2 | 0 |
| Multiple Sclerosis | 0.6 | 0.6 | 0 |
| Multiple system atrophy (MSA) | 0.3 | -0.3 | |
| myasthenia gravis | 0 | 0 | 0 |
| neuropathic pain | 0 | 0 | |
| Neuropathy (all types) | 0.2 | 0.2 | |
| neuropsychiatric disorders (PANDAS, PANS) | 0 | 0 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.6 | 0.8 | -0.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.1 | 2 |
| Obesity | 0.6 | 0.7 | -0.17 |
| obsessive-compulsive disorder | 1.3 | 0.3 | 3.33 |
| Osteoarthritis | 0.4 | 0.2 | 1 |
| Osteoporosis | 0.2 | 0.3 | -0.5 |
| pancreatic cancer | 0 | 0 | 0 |
| Parkinson's Disease | 1.2 | 0.5 | 1.4 |
| Polycystic ovary syndrome | 1.1 | 0.7 | 0.57 |
| Postural orthostatic tachycardia syndrome | 0 | 0 | 0 |
| Premenstrual dysphoric disorder | 0.2 | 0.2 | |
| primary biliary cholangitis | 0.1 | 0.1 | 0 |
| Primary sclerosing cholangitis | 0.3 | 0.9 | -2 |
| Psoriasis | 0.6 | 0.1 | 5 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.9 | 0.4 | 1.25 |
| Rosacea | 0.1 | 0 | 0 |
| Schizophrenia | 0.8 | 0.5 | 0.6 |
| scoliosis | 0 | 0.1 | 0 |
| sensorineural hearing loss | 0.1 | 0.1 | |
| Sjögren syndrome | 0.4 | 0.3 | 0.33 |
| Sleep Apnea | 0.4 | 0.3 | 0.33 |
| Slow gastric motility / Gastroparesis | 0.2 | 0 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0 | 0 |
| Stress / posttraumatic stress disorder | 0.1 | 0.1 | 0 |
| Systemic Lupus Erythematosus | 0.4 | 0.3 | 0.33 |
| Tic Disorder | 0.2 | 0 | 0 |
| Tourette syndrome | 0 | 0 | 0 |
| Type 1 Diabetes | 0.6 | 0.4 | 0.5 |
| Type 2 Diabetes | 0.5 | 0.5 | 0 |
| Ulcerative colitis | 0.4 | 0.6 | -0.5 |
| Unhealthy Ageing | 0.4 | 0 | 0 |
| Vitiligo | 0.2 | 0.1 | 1 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
